{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-079107","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2023-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.205693+00:00","generated_at":"2026-06-13T10:54:50.175464+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cyclacel gets 180-day Nasdaq extension to Jan 2, 2024 to regain $1.00 bid price compliance","bullets":["Received extension on July 5, 2023; must comply by January 2, 2024.","Previously disclosed non-compliance on Jan 6, 2023; original cure period ended July 3, 2023.","Company intends to cure via reverse stock split if necessary, within ten business days before extension expires.","If not cured by Jan 2, 2024, Nasdaq will issue delisting notice; Company may appeal to Hearing Panel."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-079107","json":"https://secwatch.observer/filing/0001104659-23-079107.json","markdown":"https://secwatch.observer/filing/0001104659-23-079107.md","text":"https://secwatch.observer/filing/0001104659-23-079107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923079107/0001104659-23-079107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923079107/tm2320788d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:54:50.175464+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb130bd673c07ff5df940068d695620c8704ebe3","claim":"Bio Green Med Solution, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"July 5, 2023, Cyclacel Pharmaceuticals, Inc. (the “ Company ”) received a letter (the “ Extension Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) notifying the Company that Nasdaq has granted the Company a 180-day extension, or until January 2, 2024 (the “ Extension Period ”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“ Common Stock ”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465923079107/0001104659-23-079107-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}